Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Cannabis Bioscience International Holdings (CBIH) Research & Development (2022 - 2025)

Cannabis Bioscience International Holdings' Research & Development history spans 4 years, with the latest figure at $62.0 for Q4 2025.

  • For Q4 2025, Research & Development fell 36.08% year-over-year to $62.0; the TTM value through Nov 2025 reached $553.0, down 31.22%, while the annual FY2025 figure was $517.0, 74.96% down from the prior year.
  • Research & Development for Q4 2025 was $62.0 at Cannabis Bioscience International Holdings, down from $213.0 in the prior quarter.
  • Across five years, Research & Development topped out at $1772.0 in Q1 2023 and bottomed at $62.0 in Q4 2025.
  • The 4-year median for Research & Development is $205.0 (2023), against an average of $547.92.
  • The largest annual shift saw Research & Development crashed 91.65% in 2024 before it surged 50.0% in 2025.
  • A 4-year view of Research & Development shows it stood at $1548.0 in 2022, then plummeted by 87.27% to $197.0 in 2023, then crashed by 50.76% to $97.0 in 2024, then crashed by 36.08% to $62.0 in 2025.
  • Per Business Quant, the three most recent readings for CBIH's Research & Development are $62.0 (Q4 2025), $213.0 (Q3 2025), and $63.0 (Q2 2025).